Cancer Family
Dermal Neoplasm
CI-CAN-00000159Explore in graph →
Non-malignant12 active trials9 evidence items
- NCIt
- C4475
Loading cancer entity…
Cancer Family
CI-CAN-00000159Explore in graph →
Clinical trials
45 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04577755 | Pomalidomide Treatment in Patients With Kaposi Sarcoma | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00050752 | Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer | recruiting | — | 1,130 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04339738 | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 2 | Sep 8, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials
| not yet recruiting |
| Phase 1 |
| 18 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT07646080 | Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans | not yet recruiting | Phase 2 | 20 | Yanjie Zhang, MDOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT07102394 | Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 | recruiting | Phase 1 | 10 | Johns Hopkins UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03601806 | Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | completed | Phase 2 | 26 | AIDS Malignancy ConsortiumNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07007273 | Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma | recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | withdrawn | Phase 2 | 0 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 0 | Jan 22, 2026 | clinicaltrials |
| NCT00975819 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | completed | Phase 2 | 61 | Denise Martin AdamsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03077451 | Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 36 | AIDS Malignancy ConsortiumNETWORK | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05581511 | Natural History Study of Cutaneous Neurofibromas in People With NF1(cNF Natural Hx) | active not recruiting | — | 500 | Johns Hopkins UniversityOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04730583 | Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06610071 | NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique(NIFR;SWIG) | not yet recruiting | Phase 1 | 592 | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOTHER | 0 | Sep 24, 2024 | clinicaltrials |
| NCT06526897 | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | not yet recruiting | N/A | 1,582 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 30, 2024 | clinicaltrials |
| NCT05438290 | DPCP to Treat Cutaneous Neurofibromas Associated With NF1 | completed | Phase 1 | 17 | Nicholas GulatiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT02110069 | A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | terminated | Phase 2 | 4 | Boston Children's HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05534854 | Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT00540566 | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | completed | — | 113 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00346164 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | completed | Phase 3 | 588 | Children's Oncology GroupNETWORK | 5 | Apr 28, 2022 | clinicaltrials |
| NCT03381846 | Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger | completed | N/A | 7 | Mayo ClinicOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02310503 | Spanish Registry of Mohs Surgery(REGESMOHS) | completed | — | 6,000 | Fundación Academia Española de DermatologíaOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT03219671 | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | unknown | Phase 2 | 20 | Alona ZerOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03090971 | Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | completed | Phase 2 | 7 | Fundação Educacional Serra dos ÓrgãosOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01059656 | Phase II Pazopanib Study in Advanced Dermatofibrosarcomas(DFSP-PAZO) | terminated | Phase 2 | 23 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT00521092 | Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 5, 2014 | clinicaltrials |
| NCT00084630 | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00243191 | Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans | completed | Phase 2 | 18 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Mar 29, 2012 | clinicaltrials |
| NCT00122473 | Imatinib in Dermatofibrosarcoma Protuberans (DFSP) | completed | Phase 1 / Phase 2 | 30 | Dermatologic Cooperative Oncology GroupOTHER | 1 | Jul 29, 2011 | clinicaltrials |